Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer

被引：1
|
作者：
Svrcek, M. [1 ]
Colle, R. [2 ]
Cayre, A. [3 ]
Mas, L. [2 ]
Bourgoin, P. [1 ]
Cohen, R. [4 ]
Andre, T. [4 ]
Penault-Llorca, F. [5 ]
Radosevic-Robin, N. [3 ]
机构：
[1] Sorbonne Univ, Hop St Antoine, Pathol, Paris, France
[2] Sorbonne Univ, Hop St Antoine, Oncol, Paris, France
[3] Univ Clermont Auvergne, INSERM, U1240, Ctr Jean Perrin,Pathol, Clermont Ferrand, France
[4] Hop St Antoine, Med Oncol Dept, Paris, France
[5] Jean Perrin Ctr, Direct Gen, BP 392, Clermont Ferrand, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.965
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
444P
引用
收藏
页码：S556 / S556
页数：1
相关论文
共 50 条
  • [1] Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).
    Svrcek, Magali
    Colle, Raphael
    Cayre, Anne
    Bourgoin, Pierre
    Cohen, Romain
    Andre, Thierry
    Penault-Llorca, Frederique Madeleine
    Radosevic-Robin, Nina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer
    Choi, Yuri
    Won, Yeo-Jin
    Lee, Sojeong
    Kim, Ahrong
    Kim, Younggeum
    Park, Won-Young
    Jo, Hong-Jae
    Song, Geun Am
    Kwon, Chae Hwa
    Park, Do Youn
    [J]. TRANSLATIONAL ONCOLOGY, 2018, 11 (03): : 764 - 770
  • [3] PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
    Sclafani, Francesco
    [J]. LANCET ONCOLOGY, 2017, 18 (09): : 1141 - 1142
  • [4] Immunotherapy Promising for Metastatic MSI-H/dMMR Colorectal Cancer
    Yarden, Ronit
    [J]. ONCOLOGY-NEW YORK, 2019, 33 (05): : 179 - 179
  • [5] NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer
    Park, Do Youn
    Choi, Chan
    Shin, Eunji
    Lee, Jae Hyuk
    Kwon, Chae Hwa
    Jo, Hong-Jae
    Kim, Hyeong-Rok
    Kim, Hyun Sung
    Oh, Nahmgun
    Lee, Ji Shin
    Park, Ok Ku
    Park, Eok
    Park, Jonghoon
    Shin, Jong-Yeon
    Kim, Jong-Il
    Seo, Jeong-Sun
    Park, Hee Dong
    Park, Joonghoon
    [J]. ONCOTARGET, 2016, 7 (07) : 8399 - 8412
  • [6] Prevalence, treatment and survival of NTRK gene fusions in microsatellite instable metastatic colorectal cancer patients
    Schraa, S.
    Lacle, M. M.
    Zwart, K.
    Gort, E. H.
    Koopman, M.
    de Leng, W.
    Vink, G.
    Bol, G. M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S703 - S703
  • [7] NTRK1 gene fusions as a novel oncogene target in lung cancer.
    Doebele, Robert Charles
    Vaishnavi, Aria
    Capelletti, Marzia
    Le, Anh T.
    Kako, Severine
    Butaney, Mohit
    Mahale, Sakshi
    Aisner, Dara L.
    Haas, Julia
    Andrews, Steven W.
    Lipson, Doron
    Stephens, Philip J.
    Varella-Garcia, Marileila
    Janne, Pasi Antero
    Miller, Vincent A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients
    Margalit, Ofer
    Stemmer, Amos
    Chapin, William J.
    Shacham-Shmueli, Einat
    Kopetz, Scott
    Andre, Thierry
    Overman, Michael J.
    Pietrantonio, Filippo
    Boursi, Ben
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [9] Development and Validation of an Ultra-Rapid Assay for Detection of NTRK1/2/3 Fusions
    Caffes, P.
    Hessler, M.
    Buglioni, A.
    Lo, Y.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S90 - S91
  • [10] NTRK1/2/3 fusions in secretory versus non-secretory breast cancers
    Wilson, T.
    Sokol, E. S.
    Ross, J. S.
    Maund, S. L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S292 - S292
12345